Clinical Trials Browser

Phase 1/2 × NETWORK × Recurrence × Clear all

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

Multiple Myeloma, Recurrence

NCT06635330 2024-10-10

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Phase 1/2 Recruiting

Burkitt Lymphoma, Recurrence